Premium
Third quarter 2020
Author(s) -
Antonis S. Manolis,
Hector Anninos
Publication year - 2020
Publication title -
oil and energy trends
Language(s) - English
Resource type - Journals
eISSN - 1744-7992
pISSN - 0950-1045
DOI - 10.1111/oet.12820
Subject(s) - quarter (canadian coin) , citation , computer science , library science , information retrieval , world wide web , history , archaeology
Rivaroxaban 2.5 mg bid plus aspirin 100 mg reduced the risk of cardiovascular (CV) events as compared with ASA monotherapy in the COMPASS trial but increased the risk of major bleedings. The current prespecified analysis was performed to assess the net clinical benefit (NCB) of adding rivaroxaban 2.5 mg bid to ASA monotherapy in patients with chronic vascular disease in the COMPASS study cohort with a specific focus on highrisk subgroups. A lower number of NCB adverse outcomes was observed with rivaroxaban 2.5 mg bid plus ASA vs ASA alone (hazard ratio, 0.80, P=0.0005), which became increasingly favorable with longer treatment duration. In selected high-risk subgroups, a larger absolute risk reduction for experiencing a NCB event was observed (Steffel J et al, Circulation 2020; 142:40-48).